Biohaven’s top regulator announced no need for an advisory committee to discuss troriluzole’s application, leading to a 6% surge in stock price. FDA informed Biohaven that the meeting was unnecessary. The drug targets spinocerebellar ataxia, and Biohaven ran new trials to support its application. Market reacts optimistically, with a history of approvals after canceled meetings. Investors advised to wait for FDA decision before buying. RBC Capital Markets analyst sees potential for approval. Biohaven not in top 10 stock picks by Motley Fool, but past picks had significant returns. Stock Advisor boasts 1,045% average return.

Read more at Nasdaq: Why Biohaven Stock Zoomed More Than 6% Higher Today